[A18-78] Tildrakizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Last updated 15.02.2019
Commission awarded on 13.11.2018 by the Federal Joint Committee (G-BA).
Skin and hair
Adults with moderate to severe plaque psoriasis who are candidates for systemic therapy
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.